- Home
- ACIU vs GNFT Comparison
ACIU vs GNFT Comparison
Compare ACIU & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- GNFT
- Stock Information
- Founded
- ACIU 2003
- GNFT 1999
- Country
- ACIU Switzerland
- GNFT France
- Employees
- ACIU N/A
- GNFT N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIU Health Care
- GNFT Health Care
- Exchange
- ACIU Nasdaq
- GNFT Nasdaq
- Market Cap
- ACIU 189.1M
- GNFT 214.5M
- IPO Year
- ACIU 2016
- GNFT 2019
- Fundamental
- Price
- ACIU $2.07
- GNFT N/A
- Analyst Decision
- ACIU Strong Buy
- GNFT Strong Buy
- Analyst Count
- ACIU 1
- GNFT 1
- Target Price
- ACIU $12.00
- GNFT $13.00
- AVG Volume (30 Days)
- ACIU 139.5K
- GNFT 4.2K
- Earning Date
- ACIU 08-05-2025
- GNFT 04-24-2025
- Dividend Yield
- ACIU N/A
- GNFT N/A
- EPS Growth
- ACIU N/A
- GNFT N/A
- EPS
- ACIU N/A
- GNFT 0.03
- Revenue
- ACIU $32,014,254.00
- GNFT $73,187,701.00
- Revenue This Year
- ACIU N/A
- GNFT $15.98
- Revenue Next Year
- ACIU $533.21
- GNFT N/A
- P/E Ratio
- ACIU N/A
- GNFT $123.88
- Revenue Growth
- ACIU 91.20
- GNFT 105.01
- 52 Week Low
- ACIU $1.43
- GNFT $2.55
- 52 Week High
- ACIU $4.26
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- ACIU 56.20
- GNFT 46.56
- Support Level
- ACIU $1.65
- GNFT $3.61
- Resistance Level
- ACIU $2.17
- GNFT $3.95
- Average True Range (ATR)
- ACIU 0.17
- GNFT 0.14
- MACD
- ACIU -0.01
- GNFT -0.01
- Stochastic Oscillator
- ACIU 70.37
- GNFT 50.64
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.